- Home
- ARQT vs TERN Comparison
ARQT vs TERN Comparison
Compare ARQT & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARQT | TERN |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ARQT | TERN |
|---|---|---|
| Price | $26.99 | $40.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $25.00 | ★ $48.60 |
| AVG Volume (30 Days) | 1.2M | ★ 1.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $86.38 | N/A |
| Revenue Next Year | $30.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.75 | $1.87 |
| 52 Week High | $31.77 | $48.26 |
Technical Indicators
Market Signals| Indicator | ARQT | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 52.62 | 63.33 |
| Support Level | $25.50 | $37.04 |
| Resistance Level | $26.97 | $39.60 |
| Average True Range (ATR) | 0.98 | 2.32 |
| MACD | 0.14 | 0.40 |
| Stochastic Oscillator | 82.37 | 97.21 |
Price Performance
Historical ComparisonAbout ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.